肾细胞癌肾上腺转移瘤经皮影像引导冷冻消融:单机构回顾性分析
本文回顾性分析了2007至2021年间单机构接受经皮影像引导冷冻消融治疗肾细胞癌肾上腺转移的46例成人患者(57个肿瘤,51次手术)。技术成功率高,局部控制良好,1年、3年和5年无复发生存率分别为100%、89%和89%,总生存率分别为98%、85%和71%。结论认为该技术安全且局部控制稳健,推荐在多学科管理下继续使用。
要点
- 46例患者共57个肾上腺转移瘤接受经皮冷冻消融,51次手术,中位住院1天。
- 技术失败2例(4%),技术有效率95%(52/55);无即刻并发症,延迟并发症4例(8%)。
- 1年、3年和5年无复发生存率分别为100%、89%和89%,总生存率分别为98%、85%和71%。
核心结论
- 经皮冷冻消融治疗肾细胞癌肾上腺转移安全且局部控制稳健,作者主张在该患者人群中继续使用。
- 推荐采用多学科管理以成功治疗。
研究设计与样本
- 回顾性、单机构综述,纳入2007至2021年间接受经皮冷冻消融的肾上腺转移性肾细胞癌成人患者。
- 共46例患者(39例男性;平均年龄66±8.8岁),57个肿瘤,51次消融手术。
- 中位住院时间为1天(范围0-3天)。
- 44例(96%)原发肿瘤为透明细胞组织学。
- 消融目的为根治性意图的肿瘤39/57(72%),其余为局部肿瘤控制。
主要发现
- 技术失败2例(4%),在剩余55例中技术有效52例(95%)。
- 无不良事件通用术语标准(CTCAE)即刻并发症;51次手术中延迟并发症4例(8%)。
- 57个肿瘤中25个(44%)出现消融部位以外的任何部位疾病进展。
- 1年、3年和5年无复发生存率分别为100%、89%和89%;总生存率分别为98%、85%和71%。
- 57例中51例(89%)术前接受α受体阻滞剂准备,56份可用记录中27例(54%)出现高血压危象,均无不良结局。
关键数值与推荐
- 技术成功定义为技术失败2例(4%),技术有效率95%(52/55)。
- 安全性:无即刻并发症,延迟并发症8%(4/51)。
- 肿瘤学结局:1年、3年和5年无复发生存率分别为100%、89%和89%;总生存率分别为98%、85%和71%。
临床怎么用
- 作者主张经皮冷冻消融可继续用于肾细胞癌肾上腺转移患者。
- 作者推荐采用多学科管理以成功治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety, technical success, disease progression, and survival associated with percutaneous image-guided cryoablation of renal cell carcinoma metastasis (mRCC) in the adrenal gland. METHODS: Retrospective, single-institution review of adult patients undergoing percutaneous cryoablation for adrenal mRCC between the years of 2007-2021. Technical parameters, technical success, safety, and survival were analyzed according to standard criteria. RESULTS: Forty-six patients (39 male; mean age 66 ± 8.8 years) with 57 tumors ablated over 51 sessions with a median hospital length of stay of 1 day (range 0-3 days). Forty-four (96%) had primary of clear cell histology. Aim of ablation was curative intent in 39 of 57 tumors (72%) with local tumor control in the remainder. There were 2 (4%) technical failures and technique efficacy was achieved in 52 out of the remaining 55 (95%). There were no Common Terminology Criteria for Adverse Events' immediate complications and 4 of 51 (8%) delayed complications. Twenty-five of 57 (44%) had disease progression anywhere, away from ablation site. One-, 3-, and 5-year recurrence free survival rates were 100%, 89%, and 89% and overall survival was 98%, 85%, and 71%. Fifty-one of 57 (89%) underwent preprocedural alpha blockade with hypertensive crisis in 27 of 56 (54%) available records, of which there were no adverse outcomes. CONCLUSION: Percutaneous cryoablation of mRCC to the adrenal glands is safe with robust local control, leading to advocacy for its ongoing use in this patient population. Multi-disciplinary management is recommended for successful treatment.
引用
- Harper KC, Atwell TD, Kassmeyer BA, et al. Percutaneous Image Guided Cryoablation of Adrenal Metastases From Renal Cell Carcinoma: A Single Institution Review. Urology. 2023. PMID: 37832831. doi:10.1016/j.urology.2023.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。